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Christopher et al. compares 15 acute myeloid leukemia patients who relapsed after 
allogeneic hematopoietic stem-cell transplantation (allo-HSCT) to 20 patients who 
relapsed after chemotherapy.  All patients had exome sequencing on paired samples 
obtained at initial presentation and at relapse.1  RNA sequencing was performed on a 
subgroup.  The authors’ note relapse after allo-HSCT is not associated with acquisition 
of unique mutations.  However, RNA sequencing revealed dysregulation of immune 
pathways.  One patient acquired PDL1/PDL2 gene amplification after allo-HSCT.  The 
authors conclude that this finding is not a common mechanism of immune escape in 
AML after transplantation.  We would caution the authors’ regarding their conclusion 
as this is a small sample size (15 patients).  A prior study revealed no PDL1/PDL2 
amplifications amongst 1273 AMLs.2  Further studies are needed to determine if 
PDL1/PDL2 amplification is only seen in AML patients who relapse after allo-HSCT.  
Hodgkin lymphoma is exquisitely sensitive to PD1 blockade due to the near-universal 
presence of PDL1/PDL2 amplification.3  Whether or not patients with AML who relapse 
after allo-HSCT and show PDL1/PDL2 amplification respond to immunotherapy 
warrants investigation.
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